US FDA approves Revolution Medicines' pancreatic cancer drug
The once-daily pill extends survival in a study of 500 adults and is approved for patients who already received treatment or cannot have combination chemotherapy.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
241 Articles
241 Articles
The U.S. FDA has approved Revolution Medicine's pancreatic cancer treatment, Rasonq. Targeting RAS mutation proteins, it has demonstrated an effect of doubling survival compared to existing anticancer drugs. It is expected to have a positive impact on the entire field of cancer treatment related to RAS mutations, including not only pancreatic cancer but also colorectal cancer and lung cancer.
FDA approves first RAS-targeted therapy for metastatic pancreatic cancer
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Pancreatic cancer’s once daily pill gets US FDA nod: What it means for therapy and India?
The approval validates an entire therapeutic strategy rather than a single drug. Patients with advanced cancer lived a median 13.2 months, compared with 6.7 months on chemotherapy. Now to be tested for lung and colorectal cancer
Metastatic Pancreatic Cancer Pills Approved in USFDA Approved Rasonque for Patients with Metastatic Pancreatic Cancer. A 30-day course in the US costs 39,800 dollars.
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
